title: The effects of ranibizumab on surgically induced endometriosis in a rat model: a preliminary study.
abstract: OBJECTIVE
  To examine the effect of ranibizumab on surgically induced endometriosis in rat models.
  
  
  METHODS
  Endometrial tissue was implanted onto the abdominal peritoneum of 20 rats that were randomized into 2 groups. The rats in group 1 (n = 9) were given 0.6 mg/kg ranibizumab on the 1st and 14th days after the second operation. The rats in group 2 (control group, n = 9) received no medication. All the rats were observed for a total of 28 days.
  
  
  RESULTS
  At the end of the treatment, the mean volume and weight of the explants in group 1 (11.49 ± 6.87 mm(3) and 36.61 ± 17.84 mg) were significantly lower than that of the control group (190.6 ± 177.4 mm(3) and 187.3 ± 174.5 mg; both Ps < .01). Mean epithelial histologic scores were significantly lower in group 1 (1.11 ± 0.78) than that of the control group (2.33 ± 0.71; P < .01). When compared with the control group, vascular endothelial growth factor (VEGF) immunoreactivities in group 1 showed statistically significant reductions (1.67 ± 0.50; 2.67 ± 0.50; P < .01).
  
  
  CONCLUSIONS
  Ranibizumab has significantly regressed the size of the endometriotic implants and caused atrophy of these lesions in rats by decreasing explant levels of VEGF.
authors.affiliation: 1Department of Obstetrics and Gynecology, Bezmialem Vakif University, School of Medicine, Istanbul, Turkey.
authors.forename: Osman
authors.initials: O
authors.lastname: Sevket
authors.forename: Asli
authors.initials: A
authors.lastname: Sevket
authors.forename: Nur
authors.initials: N
authors.lastname: Buyukpinarbasili
authors.forename: Taner
authors.initials: T
authors.lastname: Molla
authors.forename: Gokhan
authors.initials: G
authors.lastname: Kilic
authors.forename: Seda
authors.initials: S
authors.lastname: Ates
authors.forename: Ramazan
authors.initials: R
authors.lastname: Dansuk
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D010537:Peritoneum / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D011897:Random Allocation; D000069579:Ranibizumab; D051381:Rats; D017208:Rats, Wistar
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab
keywords: VEGF; endometriosis; ranibizumab